MARKET

NBIX

NBIX

Neurocrine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

98.59
+0.70
+0.72%
Closed 16:53 06/16 EDT
OPEN
97.90
PREV CLOSE
97.89
HIGH
99.47
LOW
97.47
VOLUME
577.76K
TURNOVER
--
52 WEEK HIGH
136.27
52 WEEK LOW
86.02
MARKET CAP
9.32B
P/E (TTM)
24.05
1D
5D
1M
3M
1Y
5Y
Insider Makes Significant Stock Sells in Neurocrine Biosciences (NBIX) Shares
MT Newswires · 1d ago
Insider Trends: Insider Prolongs 90-Day Selling Trend at Neurocrine Biosciences
MT Newswires · 2d ago
CFRA updates its best buys to play the vaccine-driven recovery
A look at plays for the COVID-19 vaccine recovery represents a second stab at such a list for the analysts at CFRA, which first took a run last September at
Seekingalpha · 06/03 23:15
Neurocrine Biosciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
, /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 42 Annual Global Healthcare Conference at , June 8, 2021. , Chief Executive Officer, will present at the conference.
PR Newswire - PRF · 06/01 20:01
Research Alert: CFRA Maintains Buy Opinion On Neurocrine Biosciences, Inc.
MT Newswires · 05/28 08:12
Partner Fund Management, L.P. Buys Neurocrine Biosciences Inc, Myriad Genetics Inc, Baxter ...
GuruFocus News · 05/18 20:38
Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2021
 
Benzinga · 05/18 16:16
Central Nervous System Treatment Market Size 2021 with CAGR of Value, covers the entire Covid Situation, focusing on market values , demand, trade and prices by country and product.
May 12, 2021 (The Expresswire) -- The global ”central nervous system treatment market“ size is expected to reach USD 166.53 billion by 2028, exhibiting a...
The Express Wire · 05/12 06:23
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NBIX. Analyze the recent business situations of Neurocrine through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 25 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NBIX stock price target is 122.35 with a high estimate of 163.00 and a low estimate of 98.00.
EPS
Institutional Holdings
Institutions: 585
Institutional Holdings: 106.28M
% Owned: 112.41%
Shares Outstanding: 94.55M
TypeInstitutionsShares
Increased
153
11.30M
New
71
3.30M
Decreased
125
7.76M
Sold Out
59
1.03M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.64%
Pharmaceuticals & Medical Research
-0.46%
Key Executives
Non-Executive Chairman/Independent Director
William Rastetter
Chief Executive Officer/Director
Kevin Gorman
Chief Financial Officer
Matt Abernethy
Chief Financial Officer
Matthew Abernethy
Chief Human Resource Officer
Julie Cooke
Other
Eric Benevich
Other
David Boyer
Other
Kyle Gano
Other
Dimitri Grigoriadis
Other
Malcolm Lloyd-Smith
Other
Eiry Roberts
Secretary
Darin Lippoldt
Independent Director
.. ..
Director
Johanna Mercier
Independent Director
Gary Lyons
Independent Director
George Morrow
Independent Director
Leslie Norwalk
Independent Director
Richard Pops
Independent Director
Shalini Sharp
Independent Director
Stephen Sherwin
No Data
  • All
  • Financials
  • Insiders
More
About NBIX
Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.

Webull offers kinds of Neurocrine Biosciences, Inc. stock information, including NASDAQ:NBIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBIX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBIX stock methods without spending real money on the virtual paper trading platform.